메뉴 건너뛰기




Volumn 54, Issue 2, 2010, Pages 81-88

Immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection

Author keywords

Influenza; Intramuscular injection; Pandemic; Subcutaneous injection

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; INFLUENZA A VACCINE NIBRG 14; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

EID: 76649098488     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00191.x     Document Type: Article
Times cited : (20)

References (28)
  • 1
    • 76649095097 scopus 로고    scopus 로고
    • WHO. (2009) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. Accessed July 1, 2009, at: http://www.who.int/csr/ disease/avian influenza/country/ cases table 2009 07 01/en/index.html.
    • WHO. (2009) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. Accessed July 1, 2009, at: http://www.who.int/csr/ disease/avian influenza/country/ cases table 2009 07 01/en/index.html.
  • 2
    • 76649101225 scopus 로고    scopus 로고
    • vaccine viruses developed for potential use as pre-pandemic Vaccines. Accessed July 18, at
    • WHO. (2009) Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic Vaccines. Accessed July 18, 2009, at: http://www.who.int/csr/disease/avian influenza/guidelines/ 200902 H5VaccineVirusUpdate.pdf.
    • (2009) Antigenic and genetic characteristics of H5N1 viruses and candidate , Issue.N1
  • 3
    • 76649103851 scopus 로고    scopus 로고
    • WHO. (2007) Tables on the Clinical trials of pandemic influenza prototype vaccines. WHO meeting Available at: http://www.who.int/vaccine.research/ diseases/influenza/ flu trials tables/en/index3.html.
    • WHO. (2007) Tables on the Clinical trials of pandemic influenza prototype vaccines. WHO meeting Available at: http://www.who.int/vaccine.research/ diseases/influenza/ flu trials tables/en/index3.html.
  • 4
    • 76649103543 scopus 로고    scopus 로고
    • Tashiro M. (2003) Safety and efficacy of an inactivated whole-virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).
    • Tashiro M. (2003) Safety and efficacy of an inactivated whole-virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).
  • 5
    • 2442597735 scopus 로고    scopus 로고
    • Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use
    • Hehme N., Engelmann H., KuenzelW., Neumeier E., Saenger R. (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103: 163-71.
    • (2004) Virus Res , vol.103 , pp. 163-171
    • Hehme, N.1    Engelmann, H.2    KuenzelW3    Neumeier, E.4    Saenger, R.5
  • 6
    • 0036458071 scopus 로고    scopus 로고
    • Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines
    • Hehme N., Engelmann H., KunzelW., Neumeier E., Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191: 203-8.
    • (2002) Med Microbiol Immunol , vol.191 , pp. 203-208
    • Hehme, N.1    Engelmann, H.2    KunzelW3    Neumeier, E.4    Sanger, R.5
  • 7
    • 34147181229 scopus 로고    scopus 로고
    • Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
    • Ninomiya A., Imai M., Tashiro M., Odagiri T. (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554-60.
    • (2007) Vaccine , vol.25 , pp. 3554-3560
    • Ninomiya, A.1    Imai, M.2    Tashiro, M.3    Odagiri, T.4
  • 8
    • 33344466421 scopus 로고    scopus 로고
    • Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults
    • Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. (2006) Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24: 2395-402.
    • (2006) Vaccine , vol.24 , pp. 2395-2402
    • Cook, I.F.1    Barr, I.2    Hartel, G.3    Pond, D.4    Hampson, A.W.5
  • 9
    • 76649112893 scopus 로고    scopus 로고
    • American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0-910761-85-x). p14.
    • American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0-910761-85-x). p14.
  • 10
    • 2442599892 scopus 로고    scopus 로고
    • Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine
    • Stephenson I.,Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-5.
    • (2004) Virus Res , vol.103 , pp. 91-95
    • Stephenson, I.1    Wood, J.M.2    Nicholson, K.G.3    Charlett, A.4    Zambon, M.C.5
  • 11
    • 76649090445 scopus 로고    scopus 로고
    • Committee for Proprietary Medicinal Products (CPMP)
    • European Medicine Agency, CPMP/BWP/214/96, Available at
    • European Medicine Agency. (1997) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). Available at: http://www.emea.europa.eu/ pdfs/human/ bwp/021496en.pdf.
    • (1997) Note for guidance on harmonization of requirements for influenza vaccines
  • 13
    • 33645399959 scopus 로고    scopus 로고
    • Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
    • Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T.,Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-51.
    • (2006) N Engl J Med , vol.354 , pp. 1343-1351
    • Treanor, J.J.1    Campbell, J.D.2    Zangwill, K.M.3    Rowe, T.4    Wolff, M.5
  • 14
    • 33646549355 scopus 로고    scopus 로고
    • Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial
    • Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M.,Wood J., Hoschler K., Zambon M.C. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-64.
    • (2006) Lancet , vol.367 , pp. 1657-1664
    • Bresson, J.L.1    Perronne, C.2    Launay, O.3    Gerdil, C.4    Saville, M.5    Wood, J.6    Hoschler, K.7    Zambon, M.C.8
  • 15
    • 45149129921 scopus 로고    scopus 로고
    • Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-84.
    • Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-84.
  • 16
    • 63649119320 scopus 로고    scopus 로고
    • Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M.,Wang N., YinW.D., Dong X.P. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-95.
    • Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M.,Wang N., YinW.D., Dong X.P. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-95.
  • 17
    • 34247275658 scopus 로고    scopus 로고
    • Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative study
    • Stephenson I., Das R.G.,Wood J.M., Katz J.M. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25: 4056-63.
    • (2007) Vaccine , vol.25 , pp. 4056-4063
    • Stephenson, I.1    Das, R.G.2    Wood, J.M.3    Katz, J.M.4
  • 18
    • 66449095061 scopus 로고    scopus 로고
    • Characterization of a whole, inactivated influenza (H5N1) vaccine
    • Tada Y. (2008) Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2: 261-6.
    • (2008) Influenza Other Respi Viruses , vol.2 , pp. 261-266
    • Tada, Y.1
  • 19
    • 34447544007 scopus 로고    scopus 로고
    • Kistner O., Howard M.K., Spruth M.,WodalW., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., MundtW., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-36.
    • Kistner O., Howard M.K., Spruth M.,WodalW., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., MundtW., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-36.
  • 20
    • 0015354129 scopus 로고
    • A new subunit influenza vaccine: Acceptability compared with standard vaccines and effect of dose on antigenicity
    • Ruben F.L., Jackson G.G. (1972) A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 125: 656-64.
    • (1972) J Infect Dis , vol.125 , pp. 656-664
    • Ruben, F.L.1    Jackson, G.G.2
  • 21
    • 0030581380 scopus 로고    scopus 로고
    • Immunogenicity and safety of a new inactivated hepatitis A vaccine: A clinical trial with comparison of administration route
    • Fisch A., Cadilhac P., Vidor E., Prazuck T., Dublanchet A., Lafaix C. (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14: 1132-6.
    • (1996) Vaccine , vol.14 , pp. 1132-1136
    • Fisch, A.1    Cadilhac, P.2    Vidor, E.3    Prazuck, T.4    Dublanchet, A.5    Lafaix, C.6
  • 22
    • 0032866083 scopus 로고    scopus 로고
    • Studies on a Hib-tetanus toxoid conjugate vaccine: Effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine
    • Carlsson R.M., Claesson B.A., Kayhty H., Selstam U., Iwarson S. (1999) Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 18: 468-78.
    • (1999) Vaccine , vol.18 , pp. 468-478
    • Carlsson, R.M.1    Claesson, B.A.2    Kayhty, H.3    Selstam, U.4    Iwarson, S.5
  • 23
    • 0033537873 scopus 로고    scopus 로고
    • Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents
    • Mark A., Carlsson R.M., Granstrom M. (1999) Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 17: 2067-72.
    • (1999) Vaccine , vol.17 , pp. 2067-2072
    • Mark, A.1    Carlsson, R.M.2    Granstrom, M.3
  • 27
    • 34547837401 scopus 로고    scopus 로고
    • Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial
    • Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., Leroux-Roels G. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-9.
    • (2007) Lancet , vol.370 , pp. 580-589
    • Leroux-Roels, I.1    Borkowski, A.2    Vanwolleghem, T.3    Drame, M.4    Clement, F.5    Hons, E.6    Devaster, J.M.7    Leroux-Roels, G.8
  • 28
    • 0035897889 scopus 로고    scopus 로고
    • Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza
    • Nicholson K.G., Colegate A.E., Podda A., Stephenson I.,Wood J., Ypma E., Zambon M.C. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-43.
    • (2001) Lancet , vol.357 , pp. 1937-1943
    • Nicholson, K.G.1    Colegate, A.E.2    Podda, A.3    Stephenson, I.4    Wood, J.5    Ypma, E.6    Zambon, M.C.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.